SOHO 2024 | Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

SOHO 2024 | Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4th to 7th, 2024, gathering top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new therapeutic strategies. At the conference, Dr. Eunice Wang from the Roswell Park Comprehensive Cancer Center in the United States presented the latest developments in the research and development of Menin inhibitors. For this, 'Oncology Frontier - Hematology Frontier' specially interviewed Dr. Eunice Wang and provided a wonderful interpretation around this topic.
Comparison of ASAP Score and GALAD Score in Detecting Hepatocellular Carcinoma in Chronic Liver Disease Patients with Different Etiologies

Comparison of ASAP Score and GALAD Score in Detecting Hepatocellular Carcinoma in Chronic Liver Disease Patients with Different Etiologies

Primary liver cancer ranks as the fourth most common malignancy and the second leading cause of cancer-related deaths in China, posing a severe threat to people's lives and health. Early detection, diagnosis, and treatment are crucial for improving treatment outcomes. In 2019, Dr. Feng Shen and Dr. Tian Yang research team from Eastern Hepatobiliary Surgery Hospital, collaborating with 11 renowned tertiary hospitals in China, developed the ASAP (Alpha-Fetoprotein, Age, Sex, and PIVKA-II) liver cancer risk assessment model, making a significant contribution to Chinese clinical practice.
ESMO China’s Voice | Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: Using Personalized ctDNA Methylation Haplotypes to Monitor Minimal Residual Disease After Curative Resection for Liver Cancer

ESMO China’s Voice | Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: Using Personalized ctDNA Methylation Haplotypes to Monitor Minimal Residual Disease After Curative Resection for Liver Cancer

The ESMO Annual Meeting 2024, held from September 13 to 17 in Barcelona, Spain, showcased the latest breakthroughs in oncology. Among them was a new study from the team led by Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang from Zhongshan Hospital, Fudan University, in collaboration with Burning Rock Biotech. The research, which was presented as a poster at the conference, provided preliminary evidence that the methylation and mutation of circulating tumor DNA (ctDNA) play a crucial role in assessing minimal residual disease (MRD) status and predicting recurrence after curative liver cancer surgery. This study offers new strategies and tools for postoperative management of early-stage liver cancer patients. With further refinement and large-scale clinical validation, this method could become an important adjunct in postoperative monitoring, potentially improving patient survival outcomes.
ESMO 2024 | Dr. Gabriella Pravettoni: Physical Activity is Beneficial for Cancer Patients, But Also Challenging

ESMO 2024 | Dr. Gabriella Pravettoni: Physical Activity is Beneficial for Cancer Patients, But Also Challenging

Evidence from the Breast Cancer Customization Project suggests that a more comprehensive approach is needed to help patients find the motivation to adopt an active lifestyle. Physical activity is often recommended by clinicians as a lifestyle intervention to help prevent and manage non-communicable diseases, including cancer. It is also essential for the quality of life of patients diagnosed with cancer.
ESMO China’s Voice丨Dr. Jian Li’s Team Reports on Long-Term Follow-Up of the INTRIGUE China Bridging Study

ESMO China’s Voice丨Dr. Jian Li’s Team Reports on Long-Term Follow-Up of the INTRIGUE China Bridging Study

Gastrointestinal stromal tumors (GIST) are mesenchymal tumors driven by mutations in oncogenes. In recent years, various types of small-molecule tyrosine kinase inhibitors (TKIs) have provided new treatment options for patients with advanced GIST, but there remains a significant unmet need in clinical care. During the 2024 ESMO Annual Meeting, Dr. Jian Li's team from Peking University Cancer Hospital presented updated data from the follow-up treatment analysis of the INTRIGUE China bridging study on ripretinib, offering further insights into the clinical application of such novel drugs.
ESMO 2024丨Subgroup Analysis from the ADRIATIC Study Further Supports Durvalumab Consolidation Therapy as a New Standard of Care for Limited-Stage Smal

ESMO 2024丨Subgroup Analysis from the ADRIATIC Study Further Supports Durvalumab Consolidation Therapy as a New Standard of Care for Limited-Stage Smal

From September 13 to 17, the 2024 ESMO Annual Meeting is in full swing in Barcelona, Spain. Oncology Frontier is attending the event and bringing you first-hand insights from the conference. During the non-metastatic non-small cell lung cancer (NSCLC) paper session held on September 13, Dr. Suresh Senan from Amsterdam, Netherlands, presented the latest results from the ADRIATIC study, where subgroup analysis further supports previous practice-changing findings.